News

Under the deal, Merck will acquire all of Sigma-Aldrich for $140 a share in cash, a 37% premium to Sigma’s latest closing price of $102.37. The acquisition is

Pathologic myopia and the associated myopic CNV is the second most common cause of blindness, in this country. Eylea approval is based on positive data from the Phase

ALPHANATE is used to control and prevent bleeding in patients with Hemophilia A as well as for surgical and/or invasive procedures in adult and pediatric patients with von

The company is focused on the development of new medications to help patients with cognitive disorders, including ADHD and Fragile X Syndrome. The 300-patient, randomized, placebo-controlled trial was

The contract is aimed at advancing development of the company’s thermostabilization technology, ThermoVax, combined with its ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the

The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia. Grant recipients include UNICEF, Save the Children and International

Bardet-Biedl syndrome (BBS) is an inherited disease that causes blindness, learning difficulties, extra fingers and toes and obesity and can lead to serious kidney problems. It affects around

The acquisition further accelerates Horizon’s transformation into a profitable specialty biopharmaceutical company and provides a strong operating and financial platform for future growth. The Company has over 500

In the Phase III PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, the addition of LBH589 also led to clinically meaningful increases in complete and near complete response rates